The rise in pertussis cases urges replacement of chemically-inactivated with genetically-inactivated toxoid for DTP

Vaccine

Volumn 25, Issue 15, 2007, Pages 2811-2816

  Robbins, John B ^a   Schneerson, Rachel ^a   Keith, Jerry M ^a   Shiloach, Joseph ^b   Miller, Mark ^b   Trollors, Birger ^c  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

DTP; Genetically inactivated; Pertussis toxoid

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; INACTIVATED VACCINE; PERTUSSIS TOXIN; PERTUSSIS VACCINE; TOXOID;

ANTIBODY RESPONSE; ARTICLE; BORDETELLA PERTUSSIS; DRUG EFFICACY; DRUG MANUFACTURE; HERD IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFECTION SENSITIVITY; PERTUSSIS; PRIORITY JOURNAL; SWEDEN;

BORDETELLA PERTUSSIS; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HUMANS; IMMUNITY, HERD; POLYSACCHARIDES; TOXOIDS; VACCINES, INACTIVATED; WHOOPING COUGH;

EID: 33947153768     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.12.013     Document Type: Article

References (74)

1. Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 2004. MMWR 2006;53(53):1-79 [published June 16, 2006].
2. Moerman L., Leventhal A., SLater P.E., Anis E., Yishai R., and Marva E. The re-emergence of pertussis in Israel. Israel J Med Sci 8 (2006) 308-331
3. Taranger J., Lagergard T., and Trollfors B. A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet 348 (1996) 1289-1292
4. Ipsen J. Circulating antitoxin at the onset of diphtheria in 425 patients. J Immunol 54 (1946) 325-347
5. Taranger J., Trollfors B., Bergfors E., Knutsson N., Sundh V., Lagergard T., et al. Mass vaccination of children with pertussis toxoid-decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis 33 (2001) 1004-1009
6. Bordet J., and Gengou O. Le Microbe De La Coqueluche. Ann Inst Pasteur 20 (1906) 731-741
7. Luttinger P. The epidemiology of pertussis. Am J DIs Child 12 (1916) 296-307
8. Thomas M.G., and Lambert H.P. From whom do children catch pertussis?. Br Med J 295 (1987) 751-752
9. Kendrick P., and Eldering G. Significance of bacteriological methods in the diagnosis and control of whooping cough. Am J Publ Health 25 (1935) 147-155
10. Madsen T. Vaccination against whooping cough. JAMA 101 (1933) 187-188
11. Sauer L. Whooping cough: a study in immunization. JAMA 100 (1933) 239-241
12. Kendrick P.L., Eldering G., and Dixon M.K. Mouse protection tests in the study of pertussis vaccine; a comparative series using the intracerebral route for challenge. Am J Publ Health 37 (1947) 803-810
13. Pittman M. Pertussis and pertussis vaccine control. J Wash Acad Sci 46 (1956) 234-243
14. Medical Research Council. Vaccination against whooping cough. Relation between protection tests in children and results of laboratory tests. Br Med J 2 (1956) 454-462
15. Sato H., Ito A., Chiba J., and Sato Y. Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections. Infect Immun 46 (1984) 422-428
16. Iida T., Kusano N., Yamamoto A., and Konosu M. An immunofluorescence study of the action of antibody in experimental intracerebral infection of mice with Bordetella pertussis. J Path Bact 92 (1966) 359-367
17. Kendrick P.L., Nadolski E.B., Eldering G., and Baker J. Antigenic relationships of Haemophilus pertussis, the parapertussis bacillus, and Brucella bronchiseptica as shown by cross protection tests in mice. J Bacteriol 66 (1953) 166-169
18. Watanabe M., and Munoz J.J. Comparison of biological activities of Bordetella pertussis mutants lacking the ability to produce filamentous hemagglutinin with similar activities of other smooth strains. Microbiol Immunol 26 (1982) 965-969
19. Broome C.V., and Fraser D.W. Pertussis in the United States. A look at vaccine efficacy. J Infect Dis 144 (1981) 187-190
20. Onorato I.M., Wassilak S.G., and Meade B. Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JAMA 267 (1992) 2745-2849
21. Grob P.R., Crowder M.J., and Robbins J.F. Effect of vaccination on severity and dissemination of whooping cough. Br Med J 282 (1981) 1925-1928
22. Public Health Service Research Laboratory and 21 health authorities. Efficacy of pertussis vaccination in England. Br Med J 1982;285:357-9.
23. Lambert H.J. Epidemiology of a small pertussis outbreak in Kent County, Michigan. Public Heath Rep 80 (1965) 365-369
24. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J 296 (1988) 612-614
25. Versteegh F.G.A., Mertens P.L.J.M., de Melker H.E., Roord J.J., Schellekens J.F.P., and Teunis P.F.M. Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis. Epidemiol Infect 133 (2005) 737-748
26. Préziosi M.-P., and Halloran M.E. Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness. Vaccine 21 (2003) 1853-1861
27. Linnenman C.C., Ramundo N., Perlstein P.H., Minto S.D., Englender G.S., McCormick J.B., et al. Use of pertussis vaccine in an epidemic involving hospital staff. Lancet 2 (1975) 540-543
28. Pittman M. Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis. Rev Infect Dis 1 (1979) 401-412
29. Marchitto K.S., Smith S.G., Locht C., and Keith J.M. Nucleotide sequence homology to pertussis toxin gene in Bordetella bronchiseptica and Bordetella parapertussis. Infect Immun 55 (1987) 497-501
30. Arico B., and Rappuoli R. Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes. J Bacteriol 169 (1987) 2847-2853
31. Weiss A.A., and Hewlitt E.L. Virulence factors of Bordetella pertussis. Ann Rev Microbiol 40 (1986) 661-686
32. Robbins J.B., Schneerson R., Bryla D.A., Trollfors B., Taranger J., and Lagergard T. Immunity to pertussis: not all virulence factors are protective antigens. In: Gupta S., Sher A., and Ahmed R. (Eds). Mechanisms of lymphocyte activation and immune regulation VII (1998), Plenum Press, New York, NY 207-218
33. Meade B.D., Kind P.D., Ewell J.B., McGrath P., and Manclark C.R. In-vitro inhibition of murine macrophage migration by Bordetella pertussis lymphocytosis-promoting factor. Infect Immun 45 (1984) 718-725
34. Spangrude G.J., Sacchi F., Hill H.R., Van Epps D.E., and Daynes R.A. Inhibition of lymphocyte and neutrophil chemotaxis by pertussis toxin. J Immunol 135 (1985) 4135-4143
35. Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden-Protective efficacy and adverse events. Lancet i (1988) 955-960
36. Blackwelder W.C., Storsaeter J., Olin P., and Hallander H.O. Acellular pertussis vaccines: efficacy and evaluation of clinical case definitions. Am J Dis Child 145 (1991) 1285-1289
37. WHO Criteria for Diagnosis of Pertussis-1991. WHO Meeting on case definitions of pertussis. Geneva: World Health Organization; 1991. p. 10-1 [MIM/EPI/PERT/91.1].
38. The Ad Hoc Group for the Study of Pertussis Vaccines. Randomized controlled trial of two-component, three-component, and five component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 350 (1997) 1569-1577
39. The APERT Study Group. Efficacy of acellular pertussis vaccine among adolescents and adults. N Eng J Med 353 (2005) 1555-1563
40. Centers for Disease Control. Case definitions of infectious conditions under public health surveillance. MMWR 46 (1997) 25
41. Carlsson R.-M., Claesson B.A., Lagergård T., and Trollfors B. Aquisition of serum antibodies unrelated to Bordetella pertussis infection. Clin Microbiol Infect 5 (1999) 709-712
42. Simondon F., Iteman I., Preziosi M.P., Yam A., and Guiso N. Evaluation of an immunoglobulin G enzyme-linked immunosorbent assay for pertussis toxin and filamentous hemagglutinin in diagnosis of pertussis in Senegal. Clin Diagn Lab Immunol 5 (1998) 130-134
43. von Konig W., Gounis D., Laukamp S., Bogaerts H., and Schmitt H.J. Evaluation of a single-sample serological technique for diagnosing pertussis in unvacccinated children. Eur J Microbiol Infect Dis 18 (1999) 341-345
44. Carlsson R.-M., Claesson B.O., Selstam U., Fagerlind E., Granstrom M., Blondeau C., et al. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 17 (1998) 1026-1033
45. Storsaeter J., Hallander H.O., Gustafsson L., and Olin P. Low level of antipertussis antibodies plus lack of history correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 21 (2003) 3542-3549
46. Baughman A.L., Bisnard K.M., Edwards K.M., Guris D., Ddecker M.D., Hollands K., et al. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis, filamentous hemagglutinin and fimbriae in adolescents and adults from the United States. Clin Diag Lab Immunol 11 (2004) 1045-1053
47. Watanabe M., Connell B., and Weiss A.A. Characterization of serological responses to pertussis. Clin Vaccine Immunol 13 (2006) 341-348
48. Trollfors B., Taranger J., Lågergard T., Lind L., Sundh V., Zackrisson G., et al. A placebo-controlled trial of a pertussis toxoid vaccine. N Engl J Med 333 (1995) 1045-1050
49. Robbins J.B., Schneerson R., Trollfors B., Sato H., Sato Y., Rappuoli R., et al. The diphtheria and pertussis components of DTP should be genetically-inactivated mutant toxins. J Infect Dis 191 (2005) 81-88
50. Taranger J., Trollfors B., Lagergård T., Sundh V., Bryla D.A., Schneerson R., et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 181 (2000) 1010-1013
51. Trollfors B., Taranger J., Lågergard T., Sundh V., Bryla D.A., Schneerson R., et al. Immunization of children with pertussis toxoid decreases spread of pertussis within the family. Pediatr Infect Dis J 17 (1998) 196-199
52. Hviid A., Stellfeld M., Henrick P., Andersen P.H., Fohlfarth J., and Melby M. Impact of routine vaccination with a pertussis vaccine in Denmark. Vaccine 22 (2004) 3530-3534
53. Locht C., and Keith J.M. Pertussis toxin gene: nucleotide sequence and genetic organisation. Science (USA) 232 (1986) 1258-1264
54. Nicosia A., Perugini M., Franzini C., Casagli M.C., Borri M.G., Antoni G., et al. Cloning and sequence of the pertussis toxin genes: operon structure and gene duplication. Proc Natl Acad Sci (USA) 83 (1986) 4631-4635
55. Burnette W.N., Cieplak W., Mar V.L., Kaljot K.T., Sato H., and Keith J.M. Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope. Science (USA) 242 (1988) 72-7454
56. Pizza M., Covacci A., Bartoloni A., Perugini M., Nencioni L., deMagistris M.T., et al. Mutants of pertussis toxin suitable for vaccine development. Science 246 (1989) 497-500
57. Nencioni L., Volpini G., Peppoloni S., Bugnoli M., DeMagistris T., Marsili I., et al. Properties of the pertussis toxin mutant PT-9K/129G after formaldehyde treatment. Infec Immun 59 (1990) 625-630
58. Edwards K.M., Meade B.D., Decker M.D., Reed G.F., Rennels M.R., Steinhof M.C., et al. Comparison of 12 acellular pertussis vaccines: overview and serologic response. Pediatr 96 Suppl. (1995) 548-557
59. Pichichero M.E., Deloria M.A., Rennels M.R., Anderson E.L., Edwards K.M., Decker M.D., et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15-20-month-old children. Pediatrics 100 (1997) 772-788
60. Salmasso S., Mastrantonio P., Wassilak S.G., Giulano M., Anemona A., Glammanco A., et al. Persistance of protection through 33 months of age provide by immunization in infancy with to three component acellular pertussis vaccines. Stage II Working Group. Vaccine 16 (1998) 1270-1275
61. Keitel W.A., Muenz L.R., Decker M.D., Englund J.A., Mink C.M., Blumberg D.A., et al. A randomized clinical trial of acellularr pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster development. J Infect Dis 180 (1999) 397-403
62. Knuf M., Zepp F., Mayer C., Grzegopowski E., Walter J., Riffelman M., et al. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine 34 (2006) 2043-2048
63. Nelson J.D. The changing epidemiology of pertussis in young infants: the role of adults as reservoirs of infection. Am J Dis Child 132 (1978) 371-373
64. Linnemann Jr. C.C., and Nasenbeny J. Pertussis in the adult. Ann Rev Med 28 (1977) 179-185
65. Bisnard K.M., Pascula F.B., Ehresmann K.P., Mille C.A., Clanfrini C., Jennings C.E., et al. Infant pertussis, who was the source?. Pediatr Infect Dis J 23 (2004) 959-985
66. Gangarosa E.J., Galazka A.M., Wolfe C.R., Gangarosa R.E., Miller E., and Chen R.T. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 351 (1998) 356-361
67. Smith C., and Vyas H. Early infantile pertussis: increasingly prevalent and potentially fatal. J Pediatr 159 (2000) 893-900
68. Feikin D.R., Lezotte D.C., Hamma R.F., Salmon D.A., Chen R.T., and Hoffman R.E. Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA 284 (2000) 3145-3150
69. Nennig M.E., Shinefield H.R., Edwards K.M., Black S.B., and Fireman B.H. Prevalence and incidence of adult pertussis in an urban population. JAMA 275 (1996) 1672-1674
70. Strebel P., Nordin J., Edwards K., Hunt J., Besser J., Burns S., et al. Population-based incidence of pertussis among adolescents and adults, Minnesota 1995-1996. J Infect Dis 171 (1995) 1650-1652
71. Robinson M.J., Heal C., Gardner E., Powell P., and Sims D.G. Antibody response to diphtheria-tetanus-pertussis immunization in preterm infants who received dexamethesone for chronic lung disease. Pediatrics 113 (2004) 733-737
72. Dagan R., Goldblatt D., Maleckar J.R., Yaich M., and Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with vaccine containing acellular pertussis components. Infect Immun 72 (2004) 5383-5391
73. Groom A.V., Cheek J.E., and Bryan R.T. Effect of a national vaccine shortage on vaccine coverage for American Alaska native children. Am J Public Health 96 (2006) 697-701
74. Kendrick P. Can whooping cough be eradicated?. J Infect Dis 132 (1975) 707-712